Topics:
Thoracic Malignancies • Medical Oncology
Do you offer consolidation durvalumab in stage III patients with NSCLC who developed grade 2 radiation pneumonitis during chemoradiation?
Answer from: Medical Oncologist at Community Practice
The cleanest answer is no, I would not put a patient on durvalumab who experienced pneumonitis during radiation. This is in keeping with the clinical protocol for the PACIFIC trial which excluded patients who experienced any grade pneumonitis during radiation (including grade 1). The reason we now o...
Sign in or Register to read more